abrocitinib vs IN-115314

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK1 · full Atopic Dermatitis pipeline

abrocitinib · Cibinqo

Marketed by Pfizer

Approved in Atopic Dermatitissmall molecule
Reliable signal

NCT03349060 · Phase 3 · completed

A randomized, quadruple-blind, placebo-controlled phase 3 trial enrolling 387 participants with moderate-to-severe atopic dermatitis. The co-primary endpoints (IGA response and EASI-75 at week 12) were both statistically significant for the 100 mg and 200 mg doses versus placebo, with large absolute differences (e.g. 43.8% vs 7.9% for IGA). The adequate sample size, blinded design, and positive hard clinical endpoints justify the strong evidence grade.

Next expected readout: May 2027 · NCT07848074 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2; Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30) (met)

Result source: NCT04345367

IN-115314

Developed by HK inno.N Corporation

Phase 2 in Atopic Dermatitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointabrocitinibIN-115314
EASI-7539.7% vs 11.8%+27.9 vs placebo100 mg · wk 12 · n 156NCT03349060
94 other results
  • 44.5% vs 10.4% 100 mg · wk 12 · n 155 · Phase 3 · primary NCT03575871
  • 58.7% vs 27.1% 100 mg · wk 12 · n 235 · Phase 3 · primary NCT03720470
  • 68.5% vs 41.5% 100mg QD · wk 12 · n 89 · Phase 3 · primary NCT03796676
  • 62.7% vs 11.8% 200 mg · wk 12 · n 153 · Phase 3 · primary NCT03349060
  • 61% vs 10.4% 200 mg · wk 12 · n 154 · Phase 3 · primary NCT03575871
  • 70.3% vs 27.1% 200 mg · wk 12 · n 219 · Phase 3 · primary NCT03720470
  • 72% vs 41.5% 200mg QD · wk 12 · n 93 · Phase 3 · primary NCT03796676
  • 46.5% vs 14% 100 mg · wk 52 · n 264 · Phase 3 · secondary NCT03627767
  • 54.2% vs 15.1% 100 mg · wk 40 · n 264 · Phase 3 · secondary NCT03627767
  • 60.4% vs 18% 100 mg · wk 28 · n 264 · Phase 3 · secondary NCT03627767
  • 60.3% vs 30.6% 100 mg · wk 16 · n 238 · Phase 3 · secondary NCT03720470
  • 76% vs 27% 100 mg · wk 16 · n 264 · Phase 3 · secondary NCT03627767
  • 100% vs 99.2% 100 mg · wk 12 · n 264 · Phase 3 · secondary NCT03627767
  • 38.3% vs 13.3% 100 mg · wk 8 · n 155 · Phase 3 · secondary NCT03349060
  • 43.3% vs 12.8% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • 55.6% vs 18.6% 100 mg · wk 8 · n 238 · Phase 3 · secondary NCT03720470
  • 60.4% vs 33.3% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • 27.6% vs 14.5% 100 mg · wk 4 · n 155 · Phase 3 · secondary NCT03349060
  • 26.5% vs 6.5% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • 44.6% vs 15.6% 100 mg · wk 4 · n 238 · Phase 3 · secondary NCT03720470
  • 41.3% vs 14.6% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • 10.3% vs 3.9% 100 mg · wk 2 · n 155 · Phase 3 · secondary NCT03349060
  • 10.2% vs 1.3% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • 25.4% vs 10.9% 100 mg · wk 2 · n 238 · Phase 3 · secondary NCT03720470
  • 19.6% vs 4.4% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • 65.8% vs 14% 200 mg · wk 52 · n 266 · Phase 3 · secondary NCT03627767
  • 71.8% vs 15.1% 200 mg · wk 40 · n 266 · Phase 3 · secondary NCT03627767
  • 80.5% vs 18% 200 mg · wk 28 · n 266 · Phase 3 · secondary NCT03627767
  • 71% vs 30.6% 200 mg · wk 16 · n 226 · Phase 3 · secondary NCT03720470
  • 92.5% vs 27% 200 mg · wk 16 · n 266 · Phase 3 · secondary NCT03627767
  • 99.6% vs 99.2% 200 mg · wk 12 · n 266 · Phase 3 · secondary NCT03627767
  • 57.8% vs 13.3% 200 mg · wk 8 · n 154 · Phase 3 · secondary NCT03349060
  • 60.4% vs 12.8% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • 67.9% vs 18.6% 200 mg · wk 8 · n 226 · Phase 3 · secondary NCT03720470
  • 68.5% vs 33.3% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • 47.4% vs 14.5% 200 mg · wk 4 · n 154 · Phase 3 · secondary NCT03349060
  • 51% vs 6.5% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • 57.4% vs 15.6% 200 mg · wk 4 · n 226 · Phase 3 · secondary NCT03720470
  • 63.8% vs 14.6% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • 24% vs 3.9% 200 mg · wk 2 · n 154 · Phase 3 · secondary NCT03349060
  • 24.3% vs 1.3% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • 30% vs 10.9% 200 mg · wk 2 · n 226 · Phase 3 · secondary NCT03720470
  • 25.5% vs 4.4% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • 73% vs 72.3% 200 mg QD · wk 26 · n 362 · Phase 3 · secondary NCT04345367
  • 76.1% vs 71.1% 200 mg QD · wk 20 · n 362 · Phase 3 · secondary NCT04345367
  • 77.3% vs 67.8% 200 mg QD · wk 16 · n 362 · Phase 3 · secondary NCT04345367
  • 76.3% vs 61.4% 200 mg QD · wk 12 · n 362 · Phase 3 · secondary NCT04345367
  • 71% vs 52.8% 200 mg QD · wk 8 · n 362 · Phase 3 · secondary NCT04345367
  • 57.6% vs 36.8% 200 mg QD · wk 4 · n 362 · Phase 3 · secondary NCT04345367
  • 29.4% vs 21.3% 200 mg QD · wk 2 · n 362 · Phase 3 · secondary NCT04345367
  • 25% vs 32.1% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 35% vs 31.3% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 36.8% vs 26.7% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 40.7% vs 15.4% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • 40% vs 20% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 38.2% vs 16.4% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 27.3% vs 10.9% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 12.7% vs 5.5% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 3.6% vs 3.7% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 36.8% vs 32.1% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 45.5% vs 31.3% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 55.6% vs 26.7% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 64.6% vs 15.4% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • 73.6% vs 20% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 68.5% vs 16.4% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 57.4% vs 10.9% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 36.5% vs 5.5% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 16.7% vs 3.7% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 32.1% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 6.9% vs 31.3% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 12.9% vs 26.7% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 13.3% vs 15.4% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • 22% vs 20% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 18% vs 16.4% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 20% vs 10.9% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 5.5% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 3.7% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 38.5% vs 32.1% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 25% vs 31.3% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 27.6% vs 26.7% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 17.4% vs 15.4% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • 22.4% vs 20% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 18.4% vs 16.4% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 18.4% vs 10.9% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 12.2% vs 5.5% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 3.7% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
  • 43.8% vs 0% 100 mg QD · wk 12 · n 16 · Phase 2 · secondary NCT03915496
  • 46.7% vs 0% 100 mg QD · wk 8 · n 16 · Phase 2 · secondary NCT03915496
  • 46.7% vs 0% 100 mg QD · wk 4 · n 16 · Phase 2 · secondary NCT03915496
  • 6.3% vs 0% 100 mg QD · wk 2 · n 16 · Phase 2 · secondary NCT03915496
  • 78.6% vs 0% 200 mg QD · wk 12 · n 14 · Phase 2 · secondary NCT03915496
  • 78.6% vs 0% 200 mg QD · wk 8 · n 14 · Phase 2 · secondary NCT03915496
  • 50% vs 0% 200 mg QD · wk 4 · n 14 · Phase 2 · secondary NCT03915496
  • 38.5% vs 0% 200 mg QD · wk 2 · n 14 · Phase 2 · secondary NCT03915496
—Not reported
IGA 0/1 with 2-point improvement27.8% vs 6.3%+21.5 vs placebo100mg QD · wk 12 · n 56NCT02780167
35 other results
  • 44.5% vs 6.3% 200mg QD · wk 12 · n 55 · Phase 2 · primary NCT02780167
  • 12.3% vs 6.3% 30mg QD · wk 12 · n 51 · Phase 2 · primary NCT02780167
  • 8.2% vs 6.3% 10mg QD · wk 12 · n 49 · Phase 2 · primary NCT02780167
  • 13.9% vs 10.7% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 12.5% vs 18.8% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 23.7% vs 10% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 5.5% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 12.7% vs 14.5% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 1.8% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 3.6% vs 3.6% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 1.8% vs 0% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 18.4% vs 10.7% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 15.9% vs 18.8% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 26.7% vs 10% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 41.5% vs 5.5% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 40.7% vs 14.5% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 40.7% vs 1.8% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 11.5% vs 3.6% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 0% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 7.4% vs 10.7% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 3.4% vs 18.8% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 12.9% vs 10% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 12% vs 5.5% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 14% vs 14.5% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 1.8% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 3.6% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 2% vs 0% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 23.1% vs 10.7% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 10.7% vs 18.8% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 20.7% vs 10% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 5.5% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 14.5% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 1.8% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 6.1% vs 3.6% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 0% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
—Not reported
EASI-9028.5% vs 14.6%vs Dupilumab200 mg QD · wk 4 · n 354NCT04345367
94 other results
  • 37.6% vs 10.6% 100 mg · wk 52 · n 264 · Phase 3 · secondary NCT03627767
  • 41.5% vs 12.1% 100 mg · wk 40 · n 264 · Phase 3 · secondary NCT03627767
  • 46.9% vs 10.5% 100 mg · wk 28 · n 264 · Phase 3 · secondary NCT03627767
  • 38% vs 11.3% 100 mg · wk 16 · n 238 · Phase 3 · secondary NCT03720470
  • 51.3% vs 13.9% 100 mg · wk 16 · n 264 · Phase 3 · secondary NCT03627767
  • 18.6% vs 5.3% 100 mg · wk 12 · n 156 · Phase 3 · secondary NCT03349060
  • 23.9% vs 3.9% 100 mg · wk 12 · n 158 · Phase 3 · secondary NCT03575871
  • 36.6% vs 10.1% 100 mg · wk 12 · n 238 · Phase 3 · secondary NCT03720470
  • 41.6% vs 18.1% 100mg QD · wk 12 · n 92 · Phase 3 · secondary NCT03796676
  • 87.1% vs 84.6% 100 mg · wk 12 · n 264 · Phase 3 · secondary NCT03627767
  • 14.3% vs 5.3% 100 mg · wk 8 · n 156 · Phase 3 · secondary NCT03349060
  • 17.2% vs 2.6% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • 30.6% vs 7.8% 100 mg · wk 8 · n 238 · Phase 3 · secondary NCT03720470
  • 29.7% vs 14% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • 7.9% vs 3.9% 100 mg · wk 4 · n 156 · Phase 3 · secondary NCT03349060
  • 9.7% vs 0% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • 20.2% vs 6.3% 100 mg · wk 4 · n 238 · Phase 3 · secondary NCT03720470
  • 17.4% vs 2.1% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • 1.9% vs 1.3% 100 mg · wk 2 · n 156 · Phase 3 · secondary NCT03349060
  • 2.5% vs 0% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • 8.3% vs 2.3% 100 mg · wk 2 · n 238 · Phase 3 · secondary NCT03720470
  • 8.7% vs 0% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • 54.5% vs 10.6% 200 mg · wk 52 · n 266 · Phase 3 · secondary NCT03627767
  • 58.7% vs 12.1% 200 mg · wk 40 · n 266 · Phase 3 · secondary NCT03627767
  • 64.5% vs 10.5% 200 mg · wk 28 · n 266 · Phase 3 · secondary NCT03627767
  • 48.9% vs 11.3% 200 mg · wk 16 · n 226 · Phase 3 · secondary NCT03720470
  • 77.1% vs 13.9% 200 mg · wk 16 · n 266 · Phase 3 · secondary NCT03627767
  • 38.6% vs 5.3% 200 mg · wk 12 · n 154 · Phase 3 · secondary NCT03349060
  • 37.7% vs 3.9% 200 mg · wk 12 · n 155 · Phase 3 · secondary NCT03575871
  • 46.1% vs 10.1% 200 mg · wk 12 · n 226 · Phase 3 · secondary NCT03720470
  • 49.5% vs 18.1% 200mg QD · wk 12 · n 94 · Phase 3 · secondary NCT03796676
  • 86.4% vs 84.6% 200 mg · wk 12 · n 266 · Phase 3 · secondary NCT03627767
  • 33.1% vs 5.3% 200 mg · wk 8 · n 154 · Phase 3 · secondary NCT03349060
  • 34.4% vs 2.6% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • 47.3% vs 7.8% 200 mg · wk 8 · n 226 · Phase 3 · secondary NCT03720470
  • 40.2% vs 14% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • 24.3% vs 3.9% 200 mg · wk 4 · n 154 · Phase 3 · secondary NCT03349060
  • 22.9% vs 0% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • 32.3% vs 6.3% 200 mg · wk 4 · n 226 · Phase 3 · secondary NCT03720470
  • 30.9% vs 2.1% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • 5.2% vs 1.3% 200 mg · wk 2 · n 154 · Phase 3 · secondary NCT03349060
  • 9.2% vs 0% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • 11.2% vs 2.3% 200 mg · wk 2 · n 226 · Phase 3 · secondary NCT03720470
  • 10.6% vs 0% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • 54.6% vs 47.6% 200 mg QD · wk 26 · n 362 · Phase 3 · secondary NCT04345367
  • 58.4% vs 45.7% 200 mg QD · wk 20 · n 362 · Phase 3 · secondary NCT04345367
  • 54.3% vs 41.9% 200 mg QD · wk 16 · n 357 · Phase 3 · secondary NCT04345367
  • 47.6% vs 33.6% 200 mg QD · wk 12 · n 362 · Phase 3 · secondary NCT04345367
  • 45.4% vs 25.4% 200 mg QD · wk 8 · n 362 · Phase 3 · secondary NCT04345367
  • 11.6% vs 7.2% 200 mg QD · wk 2 · n 362 · Phase 3 · secondary NCT04345367
  • 8.3% vs 14.3% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 17.5% vs 15.6% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 23.7% vs 10% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 25.9% vs 9.6% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • 23.6% vs 5.5% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 7.3% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 10.9% vs 1.8% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 5.5% vs 0% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 0% vs 0% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 10.5% vs 14.3% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 18.2% vs 15.6% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 31.1% vs 10% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 52.1% vs 9.6% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • 43.4% vs 5.5% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 44.4% vs 7.3% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 38.9% vs 1.8% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 19.2% vs 0% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 7.4% vs 0% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 14.3% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 0% vs 15.6% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 3.2% vs 10% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 0% vs 9.6% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 5.5% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 14% vs 7.3% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 1.8% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 4% vs 0% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 4% vs 0% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 23.1% vs 14.3% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 15.6% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 13.8% vs 10% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 10.9% vs 9.6% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • 12.2% vs 5.5% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 7.3% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 1.8% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 6.1% vs 0% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 0% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
  • 37.5% vs 0% 100 mg QD · wk 12 · n 16 · Phase 2 · secondary NCT03915496
  • 20% vs 0% 100 mg QD · wk 8 · n 16 · Phase 2 · secondary NCT03915496
  • 20% vs 0% 100 mg QD · wk 4 · n 16 · Phase 2 · secondary NCT03915496
  • 0% vs 0% 100 mg QD · wk 2 · n 16 · Phase 2 · secondary NCT03915496
  • 50% vs 0% 200 mg QD · wk 12 · n 14 · Phase 2 · secondary NCT03915496
  • 57.1% vs 0% 200 mg QD · wk 8 · n 14 · Phase 2 · secondary NCT03915496
  • 28.6% vs 0% 200 mg QD · wk 4 · n 14 · Phase 2 · secondary NCT03915496
  • 0% vs 0% 200 mg QD · wk 2 · n 14 · Phase 2 · secondary NCT03915496
—Not reported
EASI, % change-60% vs -28.6%−31.4 vs placebo100 mg · wk 12 · n 158NCT03575871
51 other results
  • -77.3% vs -63.7% 100mg QD · wk 12 · n 92 · Phase 3 · secondary NCT03796676
  • -59.5% vs -33% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • -72.6% vs -57.6% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • -54.3% vs -24.4% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • -66.1% vs -41.7% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • -39.2% vs -9% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • -51.5% vs -27.6% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • -73.3% vs -28.6% 200 mg · wk 12 · n 155 · Phase 3 · secondary NCT03575871
  • -80.6% vs -63.7% 200mg QD · wk 12 · n 94 · Phase 3 · secondary NCT03796676
  • -73.2% vs -33% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • -77.8% vs -57.6% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • -69% vs -24.4% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • -74.3% vs -41.7% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • -51.3% vs -9% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • -54.5% vs -27.6% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • -27.7% vs -35.9% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • -38.8% vs -35.5% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • -51.2% vs -29.8% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • -59.0% vs -35.2% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • -54.0% vs -36.7% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • -54.2% vs -39.2% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • -53.6% vs -24.6% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • -38.3% vs -23.5% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • -19.9% vs -12.3% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • -55.8% vs -35.9% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • -57.1% vs -35.5% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • -66.3% vs -29.8% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • -82.6% vs -35.2% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • -84.5% vs -36.7% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • -83.1% vs -39.2% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • -78.2% vs -24.6% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • -63.3% vs -23.5% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • -41.3% vs -12.3% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • -20.8% vs -35.9% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • -26.3% vs -35.5% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • -33.0% vs -29.8% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • -40.7% vs -35.2% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • -36.8% vs -36.7% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • -40.2% vs -39.2% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • -32.8% vs -24.6% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • -26.3% vs -23.5% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • -14.8% vs -12.3% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • -45.2% vs -35.9% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • -31.5% vs -35.5% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • -34.1% vs -29.8% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • -31.1% vs -35.2% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • -39.4% vs -36.7% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • -35.2% vs -39.2% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • -30.1% vs -24.6% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • -14.8% vs -23.5% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • -13.8% vs -12.3% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
—Not reported

EASI-75

abrocitinib
39.7% vs 11.8%+27.9 vs placebo100 mg · wk 12 · n 156NCT03349060
94 other results
  • 44.5% vs 10.4% 100 mg · wk 12 · n 155 · Phase 3 · primary NCT03575871
  • 58.7% vs 27.1% 100 mg · wk 12 · n 235 · Phase 3 · primary NCT03720470
  • 68.5% vs 41.5% 100mg QD · wk 12 · n 89 · Phase 3 · primary NCT03796676
  • 62.7% vs 11.8% 200 mg · wk 12 · n 153 · Phase 3 · primary NCT03349060
  • 61% vs 10.4% 200 mg · wk 12 · n 154 · Phase 3 · primary NCT03575871
  • 70.3% vs 27.1% 200 mg · wk 12 · n 219 · Phase 3 · primary NCT03720470
  • 72% vs 41.5% 200mg QD · wk 12 · n 93 · Phase 3 · primary NCT03796676
  • 46.5% vs 14% 100 mg · wk 52 · n 264 · Phase 3 · secondary NCT03627767
  • 54.2% vs 15.1% 100 mg · wk 40 · n 264 · Phase 3 · secondary NCT03627767
  • 60.4% vs 18% 100 mg · wk 28 · n 264 · Phase 3 · secondary NCT03627767
  • 60.3% vs 30.6% 100 mg · wk 16 · n 238 · Phase 3 · secondary NCT03720470
  • 76% vs 27% 100 mg · wk 16 · n 264 · Phase 3 · secondary NCT03627767
  • 100% vs 99.2% 100 mg · wk 12 · n 264 · Phase 3 · secondary NCT03627767
  • 38.3% vs 13.3% 100 mg · wk 8 · n 155 · Phase 3 · secondary NCT03349060
  • 43.3% vs 12.8% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • 55.6% vs 18.6% 100 mg · wk 8 · n 238 · Phase 3 · secondary NCT03720470
  • 60.4% vs 33.3% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • 27.6% vs 14.5% 100 mg · wk 4 · n 155 · Phase 3 · secondary NCT03349060
  • 26.5% vs 6.5% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • 44.6% vs 15.6% 100 mg · wk 4 · n 238 · Phase 3 · secondary NCT03720470
  • 41.3% vs 14.6% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • 10.3% vs 3.9% 100 mg · wk 2 · n 155 · Phase 3 · secondary NCT03349060
  • 10.2% vs 1.3% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • 25.4% vs 10.9% 100 mg · wk 2 · n 238 · Phase 3 · secondary NCT03720470
  • 19.6% vs 4.4% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • 65.8% vs 14% 200 mg · wk 52 · n 266 · Phase 3 · secondary NCT03627767
  • 71.8% vs 15.1% 200 mg · wk 40 · n 266 · Phase 3 · secondary NCT03627767
  • 80.5% vs 18% 200 mg · wk 28 · n 266 · Phase 3 · secondary NCT03627767
  • 71% vs 30.6% 200 mg · wk 16 · n 226 · Phase 3 · secondary NCT03720470
  • 92.5% vs 27% 200 mg · wk 16 · n 266 · Phase 3 · secondary NCT03627767
  • 99.6% vs 99.2% 200 mg · wk 12 · n 266 · Phase 3 · secondary NCT03627767
  • 57.8% vs 13.3% 200 mg · wk 8 · n 154 · Phase 3 · secondary NCT03349060
  • 60.4% vs 12.8% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • 67.9% vs 18.6% 200 mg · wk 8 · n 226 · Phase 3 · secondary NCT03720470
  • 68.5% vs 33.3% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • 47.4% vs 14.5% 200 mg · wk 4 · n 154 · Phase 3 · secondary NCT03349060
  • 51% vs 6.5% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • 57.4% vs 15.6% 200 mg · wk 4 · n 226 · Phase 3 · secondary NCT03720470
  • 63.8% vs 14.6% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • 24% vs 3.9% 200 mg · wk 2 · n 154 · Phase 3 · secondary NCT03349060
  • 24.3% vs 1.3% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • 30% vs 10.9% 200 mg · wk 2 · n 226 · Phase 3 · secondary NCT03720470
  • 25.5% vs 4.4% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • 73% vs 72.3% 200 mg QD · wk 26 · n 362 · Phase 3 · secondary NCT04345367
  • 76.1% vs 71.1% 200 mg QD · wk 20 · n 362 · Phase 3 · secondary NCT04345367
  • 77.3% vs 67.8% 200 mg QD · wk 16 · n 362 · Phase 3 · secondary NCT04345367
  • 76.3% vs 61.4% 200 mg QD · wk 12 · n 362 · Phase 3 · secondary NCT04345367
  • 71% vs 52.8% 200 mg QD · wk 8 · n 362 · Phase 3 · secondary NCT04345367
  • 57.6% vs 36.8% 200 mg QD · wk 4 · n 362 · Phase 3 · secondary NCT04345367
  • 29.4% vs 21.3% 200 mg QD · wk 2 · n 362 · Phase 3 · secondary NCT04345367
  • 25% vs 32.1% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 35% vs 31.3% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 36.8% vs 26.7% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 40.7% vs 15.4% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • 40% vs 20% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 38.2% vs 16.4% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 27.3% vs 10.9% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 12.7% vs 5.5% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 3.6% vs 3.7% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 36.8% vs 32.1% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 45.5% vs 31.3% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 55.6% vs 26.7% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 64.6% vs 15.4% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • 73.6% vs 20% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 68.5% vs 16.4% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 57.4% vs 10.9% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 36.5% vs 5.5% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 16.7% vs 3.7% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 32.1% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 6.9% vs 31.3% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 12.9% vs 26.7% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 13.3% vs 15.4% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • 22% vs 20% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 18% vs 16.4% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 20% vs 10.9% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 5.5% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 3.7% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 38.5% vs 32.1% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 25% vs 31.3% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 27.6% vs 26.7% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 17.4% vs 15.4% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • 22.4% vs 20% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 18.4% vs 16.4% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 18.4% vs 10.9% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 12.2% vs 5.5% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 3.7% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
  • 43.8% vs 0% 100 mg QD · wk 12 · n 16 · Phase 2 · secondary NCT03915496
  • 46.7% vs 0% 100 mg QD · wk 8 · n 16 · Phase 2 · secondary NCT03915496
  • 46.7% vs 0% 100 mg QD · wk 4 · n 16 · Phase 2 · secondary NCT03915496
  • 6.3% vs 0% 100 mg QD · wk 2 · n 16 · Phase 2 · secondary NCT03915496
  • 78.6% vs 0% 200 mg QD · wk 12 · n 14 · Phase 2 · secondary NCT03915496
  • 78.6% vs 0% 200 mg QD · wk 8 · n 14 · Phase 2 · secondary NCT03915496
  • 50% vs 0% 200 mg QD · wk 4 · n 14 · Phase 2 · secondary NCT03915496
  • 38.5% vs 0% 200 mg QD · wk 2 · n 14 · Phase 2 · secondary NCT03915496
IN-115314
—Not reported

IGA 0/1 with 2-point improvement

abrocitinib
27.8% vs 6.3%+21.5 vs placebo100mg QD · wk 12 · n 56NCT02780167
35 other results
  • 44.5% vs 6.3% 200mg QD · wk 12 · n 55 · Phase 2 · primary NCT02780167
  • 12.3% vs 6.3% 30mg QD · wk 12 · n 51 · Phase 2 · primary NCT02780167
  • 8.2% vs 6.3% 10mg QD · wk 12 · n 49 · Phase 2 · primary NCT02780167
  • 13.9% vs 10.7% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 12.5% vs 18.8% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 23.7% vs 10% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 5.5% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 12.7% vs 14.5% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 1.8% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 3.6% vs 3.6% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 1.8% vs 0% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 18.4% vs 10.7% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 15.9% vs 18.8% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 26.7% vs 10% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 41.5% vs 5.5% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 40.7% vs 14.5% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 40.7% vs 1.8% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 11.5% vs 3.6% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 0% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 7.4% vs 10.7% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 3.4% vs 18.8% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 12.9% vs 10% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 12% vs 5.5% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 14% vs 14.5% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 1.8% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 3.6% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 2% vs 0% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 23.1% vs 10.7% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 10.7% vs 18.8% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 20.7% vs 10% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 5.5% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 14.5% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 1.8% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 6.1% vs 3.6% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 0% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
IN-115314
—Not reported

EASI-90

abrocitinib
28.5% vs 14.6%vs Dupilumab200 mg QD · wk 4 · n 354NCT04345367
94 other results
  • 37.6% vs 10.6% 100 mg · wk 52 · n 264 · Phase 3 · secondary NCT03627767
  • 41.5% vs 12.1% 100 mg · wk 40 · n 264 · Phase 3 · secondary NCT03627767
  • 46.9% vs 10.5% 100 mg · wk 28 · n 264 · Phase 3 · secondary NCT03627767
  • 38% vs 11.3% 100 mg · wk 16 · n 238 · Phase 3 · secondary NCT03720470
  • 51.3% vs 13.9% 100 mg · wk 16 · n 264 · Phase 3 · secondary NCT03627767
  • 18.6% vs 5.3% 100 mg · wk 12 · n 156 · Phase 3 · secondary NCT03349060
  • 23.9% vs 3.9% 100 mg · wk 12 · n 158 · Phase 3 · secondary NCT03575871
  • 36.6% vs 10.1% 100 mg · wk 12 · n 238 · Phase 3 · secondary NCT03720470
  • 41.6% vs 18.1% 100mg QD · wk 12 · n 92 · Phase 3 · secondary NCT03796676
  • 87.1% vs 84.6% 100 mg · wk 12 · n 264 · Phase 3 · secondary NCT03627767
  • 14.3% vs 5.3% 100 mg · wk 8 · n 156 · Phase 3 · secondary NCT03349060
  • 17.2% vs 2.6% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • 30.6% vs 7.8% 100 mg · wk 8 · n 238 · Phase 3 · secondary NCT03720470
  • 29.7% vs 14% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • 7.9% vs 3.9% 100 mg · wk 4 · n 156 · Phase 3 · secondary NCT03349060
  • 9.7% vs 0% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • 20.2% vs 6.3% 100 mg · wk 4 · n 238 · Phase 3 · secondary NCT03720470
  • 17.4% vs 2.1% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • 1.9% vs 1.3% 100 mg · wk 2 · n 156 · Phase 3 · secondary NCT03349060
  • 2.5% vs 0% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • 8.3% vs 2.3% 100 mg · wk 2 · n 238 · Phase 3 · secondary NCT03720470
  • 8.7% vs 0% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • 54.5% vs 10.6% 200 mg · wk 52 · n 266 · Phase 3 · secondary NCT03627767
  • 58.7% vs 12.1% 200 mg · wk 40 · n 266 · Phase 3 · secondary NCT03627767
  • 64.5% vs 10.5% 200 mg · wk 28 · n 266 · Phase 3 · secondary NCT03627767
  • 48.9% vs 11.3% 200 mg · wk 16 · n 226 · Phase 3 · secondary NCT03720470
  • 77.1% vs 13.9% 200 mg · wk 16 · n 266 · Phase 3 · secondary NCT03627767
  • 38.6% vs 5.3% 200 mg · wk 12 · n 154 · Phase 3 · secondary NCT03349060
  • 37.7% vs 3.9% 200 mg · wk 12 · n 155 · Phase 3 · secondary NCT03575871
  • 46.1% vs 10.1% 200 mg · wk 12 · n 226 · Phase 3 · secondary NCT03720470
  • 49.5% vs 18.1% 200mg QD · wk 12 · n 94 · Phase 3 · secondary NCT03796676
  • 86.4% vs 84.6% 200 mg · wk 12 · n 266 · Phase 3 · secondary NCT03627767
  • 33.1% vs 5.3% 200 mg · wk 8 · n 154 · Phase 3 · secondary NCT03349060
  • 34.4% vs 2.6% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • 47.3% vs 7.8% 200 mg · wk 8 · n 226 · Phase 3 · secondary NCT03720470
  • 40.2% vs 14% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • 24.3% vs 3.9% 200 mg · wk 4 · n 154 · Phase 3 · secondary NCT03349060
  • 22.9% vs 0% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • 32.3% vs 6.3% 200 mg · wk 4 · n 226 · Phase 3 · secondary NCT03720470
  • 30.9% vs 2.1% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • 5.2% vs 1.3% 200 mg · wk 2 · n 154 · Phase 3 · secondary NCT03349060
  • 9.2% vs 0% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • 11.2% vs 2.3% 200 mg · wk 2 · n 226 · Phase 3 · secondary NCT03720470
  • 10.6% vs 0% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • 54.6% vs 47.6% 200 mg QD · wk 26 · n 362 · Phase 3 · secondary NCT04345367
  • 58.4% vs 45.7% 200 mg QD · wk 20 · n 362 · Phase 3 · secondary NCT04345367
  • 54.3% vs 41.9% 200 mg QD · wk 16 · n 357 · Phase 3 · secondary NCT04345367
  • 47.6% vs 33.6% 200 mg QD · wk 12 · n 362 · Phase 3 · secondary NCT04345367
  • 45.4% vs 25.4% 200 mg QD · wk 8 · n 362 · Phase 3 · secondary NCT04345367
  • 11.6% vs 7.2% 200 mg QD · wk 2 · n 362 · Phase 3 · secondary NCT04345367
  • 8.3% vs 14.3% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 17.5% vs 15.6% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 23.7% vs 10% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 25.9% vs 9.6% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • 23.6% vs 5.5% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 7.3% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 10.9% vs 1.8% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 5.5% vs 0% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 0% vs 0% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 10.5% vs 14.3% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 18.2% vs 15.6% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 31.1% vs 10% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 52.1% vs 9.6% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • 43.4% vs 5.5% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 44.4% vs 7.3% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 38.9% vs 1.8% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 19.2% vs 0% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 7.4% vs 0% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 14.3% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 0% vs 15.6% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 3.2% vs 10% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 0% vs 9.6% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 5.5% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 14% vs 7.3% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 1.8% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 4% vs 0% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 4% vs 0% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 23.1% vs 14.3% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 15.6% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 13.8% vs 10% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 10.9% vs 9.6% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • 12.2% vs 5.5% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 7.3% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 1.8% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 6.1% vs 0% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 0% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
  • 37.5% vs 0% 100 mg QD · wk 12 · n 16 · Phase 2 · secondary NCT03915496
  • 20% vs 0% 100 mg QD · wk 8 · n 16 · Phase 2 · secondary NCT03915496
  • 20% vs 0% 100 mg QD · wk 4 · n 16 · Phase 2 · secondary NCT03915496
  • 0% vs 0% 100 mg QD · wk 2 · n 16 · Phase 2 · secondary NCT03915496
  • 50% vs 0% 200 mg QD · wk 12 · n 14 · Phase 2 · secondary NCT03915496
  • 57.1% vs 0% 200 mg QD · wk 8 · n 14 · Phase 2 · secondary NCT03915496
  • 28.6% vs 0% 200 mg QD · wk 4 · n 14 · Phase 2 · secondary NCT03915496
  • 0% vs 0% 200 mg QD · wk 2 · n 14 · Phase 2 · secondary NCT03915496
IN-115314
—Not reported

EASI, % change

abrocitinib
-60% vs -28.6%−31.4 vs placebo100 mg · wk 12 · n 158NCT03575871
51 other results
  • -77.3% vs -63.7% 100mg QD · wk 12 · n 92 · Phase 3 · secondary NCT03796676
  • -59.5% vs -33% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • -72.6% vs -57.6% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • -54.3% vs -24.4% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • -66.1% vs -41.7% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • -39.2% vs -9% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • -51.5% vs -27.6% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • -73.3% vs -28.6% 200 mg · wk 12 · n 155 · Phase 3 · secondary NCT03575871
  • -80.6% vs -63.7% 200mg QD · wk 12 · n 94 · Phase 3 · secondary NCT03796676
  • -73.2% vs -33% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • -77.8% vs -57.6% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • -69% vs -24.4% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • -74.3% vs -41.7% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • -51.3% vs -9% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • -54.5% vs -27.6% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • -27.7% vs -35.9% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • -38.8% vs -35.5% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • -51.2% vs -29.8% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • -59.0% vs -35.2% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • -54.0% vs -36.7% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • -54.2% vs -39.2% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • -53.6% vs -24.6% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • -38.3% vs -23.5% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • -19.9% vs -12.3% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • -55.8% vs -35.9% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • -57.1% vs -35.5% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • -66.3% vs -29.8% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • -82.6% vs -35.2% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • -84.5% vs -36.7% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • -83.1% vs -39.2% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • -78.2% vs -24.6% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • -63.3% vs -23.5% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • -41.3% vs -12.3% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • -20.8% vs -35.9% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • -26.3% vs -35.5% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • -33.0% vs -29.8% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • -40.7% vs -35.2% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • -36.8% vs -36.7% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • -40.2% vs -39.2% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • -32.8% vs -24.6% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • -26.3% vs -23.5% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • -14.8% vs -12.3% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • -45.2% vs -35.9% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • -31.5% vs -35.5% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • -34.1% vs -29.8% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • -31.1% vs -35.2% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • -39.4% vs -36.7% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • -35.2% vs -39.2% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • -30.1% vs -24.6% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • -14.8% vs -23.5% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • -13.8% vs -12.3% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
IN-115314
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

IN-115314: no structured comparison results are available for Atopic Dermatitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. abrocitinib: 4 of 4 rows · IN-115314: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricabrocitinib
Dropout rate
13.5%100 mga
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 24 more results
11%200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
9.7%200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
13.3%100 mg
NCT03575871 · Phase 3
9%200 mg
NCT03575871 · Phase 3
—100 mg
NCT03720470 · Phase 3
8.8%100 mg
NCT03720470 · Phase 3
—200 mg
NCT03720470 · Phase 3
8%200 mg
NCT03720470 · Phase 3
3.2%100mg QD
NCT03796676 · Phase 3
3.2%200mg QD
NCT03796676 · Phase 3
6.9%100 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
—100 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
8.1%200 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
—200 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
35.4%200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
12.5%100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
7.1%200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
33.9%100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
30.9%200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
47.1%30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
44.9%10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
5.8%100 mga
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 24 more results
5.8%200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3%200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.2%100 mg
NCT03575871 · Phase 3
3.2%200 mg
NCT03575871 · Phase 3
—100 mg
NCT03720470 · Phase 3
2.5%100 mg
NCT03720470 · Phase 3
—200 mg
NCT03720470 · Phase 3
4%200 mg
NCT03720470 · Phase 3
1.1%100mg QD
NCT03796676 · Phase 3
2.1%200mg QD
NCT03796676 · Phase 3
0%100 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
—100 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
1%200 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
—200 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
4%200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
12.5%100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
7.1%200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
21.4%100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
14.5%200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
15.7%30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
16.3%10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
Serious AEs
3.2%100 mga
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 24 more results
3.2%200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.7%200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.2%100 mg
NCT03575871 · Phase 3
1.3%200 mg
NCT03575871 · Phase 3
2.5%100 mg
NCT03720470 · Phase 3
0.5%100 mg
NCT03720470 · Phase 3
0.9%200 mg
NCT03720470 · Phase 3
0%200 mg
NCT03720470 · Phase 3
0%100mg QD
NCT03796676 · Phase 3
1.1%200mg QD
NCT03796676 · Phase 3
1%100 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
0%200 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
0%200 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
3.4%100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.6%200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
5.3%200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.1%200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0%100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
0%200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
5.4%100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
3.6%200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
0%30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
4.1%10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mga
nasopharyngitis 14.7% (placebo 10.4%)
dermatitis atopic 14.1% (placebo 16.9%)
nausea 9% (placebo 2.6%)
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 24 more results
200 mg
nausea 20.1% (placebo 2.6%)
nasopharyngitis 11.7% (placebo 10.4%)
headache 9.7% (placebo 2.6%)
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
200 mg QD
nausea 19.3%
headache 13%
acne 12.7%
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
100 mg
nasopharyngitis 12.7% (placebo 6.4%)
upper respiratory tract infection 8.9% (placebo 3.8%)
nausea 7.6% (placebo 2.6%)
NCT03575871 · Phase 3
200 mg
nausea 14.2% (placebo 2.6%)
headache 7.7% (placebo 2.6%)
nasopharyngitis 7.7% (placebo 6.4%)
NCT03575871 · Phase 3
100 mg
nasopharyngitis 9.2% (placebo 6.9%)
upper respiratory tract infection 5% (placebo 4.6%)
headache 4.2% (placebo 4.6%)
NCT03720470 · Phase 3
100 mg
upper respiratory tract infection 2.8% (placebo 4.6%)
cough 1.4% (placebo 1.5%)
diarrhoea 1.4% (placebo 3.1%)
NCT03720470 · Phase 3
200 mg
nausea 11.1% (placebo 1.5%)
acne 6.6% (placebo 0%)
headache 6.6% (placebo 4.6%)
NCT03720470 · Phase 3
200 mg
nasopharyngitis 4.3% (placebo 6.9%)
upper respiratory tract infection 2.4% (placebo 4.6%)
dermatitis atopic 1.9% (placebo 3.1%)
NCT03720470 · Phase 3
100mg QD
upper respiratory tract infection 9.5% (placebo 10.4%)
nasopharyngitis 8.4% (placebo 9.4%)
folliculitis 7.4% (placebo 1%)
NCT03796676 · Phase 3
200mg QD
nausea 18.1% (placebo 1%)
upper respiratory tract infection 10.6% (placebo 10.4%)
headache 8.5% (placebo 7.3%)
NCT03796676 · Phase 3
100 mg QD
nausea 5%
dermatitis atopic 4%
alanine aminotransferase increased 3%
NCT05375929 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 10.5%
nausea 10.5%
cough 5.3%
NCT05375929 · Phase 3 · registry result, not featured evidence
200 mg QD
nausea 9.1%
gastrooesophageal reflux disease 4%
pruritus 4%
NCT05375929 · Phase 3 · registry result, not featured evidence
200 mg
dermatitis atopic 12.5%
pyrexia 12.5%
asthma 6.3%
NCT05375929 · Phase 3 · registry result, not featured evidence
100 mg
dermatitis atopic 21.1% (placebo 33%)
nausea 13.2% (placebo 16.5%)
nasopharyngitis 10.2% (placebo 9.7%)
NCT03627767 · Phase 3 · registry result, not featured evidence
200 mg
nausea 16.1% (placebo 16.5%)
headache 9.7% (placebo 11.6%)
nasopharyngitis 6.2% (placebo 9.7%)
NCT03627767 · Phase 3 · registry result, not featured evidence
200 mg
nausea 18.4% (placebo 16.5%)
dermatitis atopic 13.5% (placebo 33%)
acne 11.7% (placebo 7.1%)
NCT03627767 · Phase 3 · registry result, not featured evidence
200 mg
upper respiratory tract infection 6% (placebo 9.7%)
nasopharyngitis 4.8% (placebo 9.7%)
dermatitis atopic 3.7% (placebo 33%)
NCT03627767 · Phase 3 · registry result, not featured evidence
100 mg QD
nausea 18.8% (placebo 6.3%)
dizziness 12.5% (placebo 0%)
abdominal discomfort 6.3% (placebo 0%)
NCT03915496 · Phase 2 · registry result, not featured evidence
200 mg QD
nausea 28.6% (placebo 6.3%)
headache 14.3% (placebo 0%)
abdominal distension 7.1% (placebo 0%)
NCT03915496 · Phase 2 · registry result, not featured evidence
100mg QD
viral upper respiratory tract infection 17.9% (placebo 8.9%)
dermatitis atopic 12.5% (placebo 10.7%)
headache 8.9% (placebo 3.6%)
NCT02780167 · Phase 2 · registry result, not featured evidence
200mg QD
nausea 14.5% (placebo 1.8%)
dermatitis atopic 12.7% (placebo 10.7%)
viral upper respiratory tract infection 12.7% (placebo 8.9%)
NCT02780167 · Phase 2 · registry result, not featured evidence
30mg QD
dermatitis atopic 17.6% (placebo 10.7%)
viral upper respiratory tract infection 11.8% (placebo 8.9%)
headache 9.8% (placebo 3.6%)
NCT02780167 · Phase 2 · registry result, not featured evidence
10mg QD
dermatitis atopic 16.3% (placebo 10.7%)
viral upper respiratory tract infection 10.2% (placebo 8.9%)
diarrhoea 6.1% (placebo 1.8%)
NCT02780167 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 22 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

abrocitinib

IGA 0/1 23.7% (n=156) vs 7.9% (n=76) placebo @ 12wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 40 more results
3.9% (n=155) vs 0% (n=77) placebo @ 2wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10.5% (n=155) vs 5.3% (n=77) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
20.3% (n=155) vs 6.7% (n=77) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
28.4% (n=155) vs 9.1% (n=77) placebo @ 12wk100 mg
NCT03575871 · Phase 3
5.1% (n=158) vs 0% (n=78) placebo @ 2wk100 mg
NCT03575871 · Phase 3
14.2% (n=158) vs 1.3% (n=78) placebo @ 4wk100 mg
NCT03575871 · Phase 3
22.3% (n=158) vs 10.3% (n=78) placebo @ 8wk100 mg
NCT03575871 · Phase 3
99.6% (n=264) vs 99.6% (n=267) placebo @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
55.5% (n=264) vs 15.4% (n=267) placebo @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
45% (n=264) vs 10.5% (n=267) placebo @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
42.3% (n=264) vs 10.6% (n=267) placebo @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
36.8% (n=264) vs 11.7% (n=267) placebo @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0% (n=16) vs 0% (n=16) placebo @ 2wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
26.7% (n=16) vs 0% (n=16) placebo @ 4wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
26.7% (n=16) vs 0% (n=16) placebo @ 8wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
25% (n=16) vs 0% (n=16) placebo @ 12wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
43.8% (n=153) vs 7.9% (n=76) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
9.7% (n=154) vs 0% (n=77) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
27% (n=154) vs 5.3% (n=77) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
35.7% (n=154) vs 6.7% (n=77) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
14.4% (n=362) vs 7.2% (n=365) Dupilumab @ 2wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
38% (n=362) vs 17.6% (n=365) Dupilumab @ 4wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
50.1% (n=362) vs 30.9% (n=365) Dupilumab @ 8wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
51.8% (n=362) vs 36% (n=365) Dupilumab @ 12wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
55.3% (n=362) vs 42.5% (n=365) Dupilumab @ 16wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
60% (n=362) vs 50.8% (n=365) Dupilumab @ 20wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
55.6% (n=362) vs 51.1% (n=365) Dupilumab @ 26wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
38.1% (n=155) vs 9.1% (n=77) placebo @ 12wk200 mg
NCT03575871 · Phase 3
14.5% (n=155) vs 0% (n=78) placebo @ 2wk200 mg
NCT03575871 · Phase 3
33.3% (n=155) vs 1.3% (n=78) placebo @ 4wk200 mg
NCT03575871 · Phase 3
37.7% (n=155) vs 10.3% (n=78) placebo @ 8wk200 mg
NCT03575871 · Phase 3
99.2% (n=266) vs 99.6% (n=267) placebo @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
77.8% (n=266) vs 15.4% (n=267) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
61.8% (n=266) vs 10.5% (n=267) placebo @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
57.1% (n=266) vs 10.6% (n=267) placebo @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
54.1% (n=266) vs 11.7% (n=267) placebo @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
7.7% (n=14) vs 0% (n=16) placebo @ 2wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
35.7% (n=14) vs 0% (n=16) placebo @ 4wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
64.3% (n=14) vs 0% (n=16) placebo @ 8wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
57.1% (n=14) vs 0% (n=16) placebo @ 12wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
EASI-75 39.7% (n=156) vs 11.8% (n=76) placebo @ 12wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 94 more results
10.3% (n=155) vs 3.9% (n=77) placebo @ 2wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
27.6% (n=155) vs 14.5% (n=77) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
38.3% (n=155) vs 13.3% (n=77) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
44.5% (n=155) vs 10.4% (n=77) placebo @ 12wk100 mg
NCT03575871 · Phase 3
10.2% (n=158) vs 1.3% (n=78) placebo @ 2wk100 mg
NCT03575871 · Phase 3
26.5% (n=158) vs 6.5% (n=78) placebo @ 4wk100 mg
NCT03575871 · Phase 3
43.3% (n=158) vs 12.8% (n=78) placebo @ 8wk100 mg
NCT03575871 · Phase 3
58.7% (n=235) vs 27.1% (n=129) placebo @ 12wk100 mg
NCT03720470 · Phase 3
25.4% (n=238) vs 10.9% (n=131) placebo @ 2wk100 mg
NCT03720470 · Phase 3
44.6% (n=238) vs 15.6% (n=131) placebo @ 4wk100 mg
NCT03720470 · Phase 3
55.6% (n=238) vs 18.6% (n=131) placebo @ 8wk100 mg
NCT03720470 · Phase 3
60.3% (n=238) vs 30.6% (n=131) placebo @ 16wk100 mg
NCT03720470 · Phase 3
68.5% (n=89) vs 41.5% (n=94) placebo @ 12wk100mg QD
NCT03796676 · Phase 3
19.6% (n=92) vs 4.4% (n=96) placebo @ 2wk100mg QD
NCT03796676 · Phase 3
41.3% (n=92) vs 14.6% (n=96) placebo @ 4wk100mg QD
NCT03796676 · Phase 3
60.4% (n=92) vs 33.3% (n=96) placebo @ 8wk100mg QD
NCT03796676 · Phase 3
100% (n=264) vs 99.2% (n=267) placebo @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
76% (n=264) vs 27% (n=267) placebo @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
60.4% (n=264) vs 18% (n=267) placebo @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
54.2% (n=264) vs 15.1% (n=267) placebo @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
46.5% (n=264) vs 14% (n=267) placebo @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
6.3% (n=16) vs 0% (n=16) placebo @ 2wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
46.7% (n=16) vs 0% (n=16) placebo @ 4wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
46.7% (n=16) vs 0% (n=16) placebo @ 8wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
43.8% (n=16) vs 0% (n=16) placebo @ 12wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
3.6% (n=56) vs 3.7% (n=56) placebo @ 1wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
12.7% (n=56) vs 5.5% (n=56) placebo @ 2wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
27.3% (n=56) vs 10.9% (n=56) placebo @ 4wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
38.2% (n=56) vs 16.4% (n=56) placebo @ 6wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
40% (n=56) vs 20% (n=56) placebo @ 8wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
40.7% (n=56) vs 15.4% (n=56) placebo @ 12wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
36.8% (n=56) vs 26.7% (n=56) placebo @ 13wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
35% (n=56) vs 31.3% (n=56) placebo @ 14wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
25% (n=56) vs 32.1% (n=56) placebo @ 16wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
62.7% (n=153) vs 11.8% (n=76) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
24% (n=154) vs 3.9% (n=77) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
47.4% (n=154) vs 14.5% (n=77) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
57.8% (n=154) vs 13.3% (n=77) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
29.4% (n=362) vs 21.3% (n=365) Dupilumab @ 2wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
57.6% (n=362) vs 36.8% (n=365) Dupilumab @ 4wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
71% (n=362) vs 52.8% (n=365) Dupilumab @ 8wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
76.3% (n=362) vs 61.4% (n=365) Dupilumab @ 12wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
77.3% (n=362) vs 67.8% (n=365) Dupilumab @ 16wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
76.1% (n=362) vs 71.1% (n=365) Dupilumab @ 20wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
73% (n=362) vs 72.3% (n=365) Dupilumab @ 26wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
61% (n=154) vs 10.4% (n=77) placebo @ 12wk200 mg
NCT03575871 · Phase 3
24.3% (n=155) vs 1.3% (n=78) placebo @ 2wk200 mg
NCT03575871 · Phase 3
51% (n=155) vs 6.5% (n=78) placebo @ 4wk200 mg
NCT03575871 · Phase 3
60.4% (n=155) vs 12.8% (n=78) placebo @ 8wk200 mg
NCT03575871 · Phase 3
70.3% (n=219) vs 27.1% (n=129) placebo @ 12wk200 mg
NCT03720470 · Phase 3
30% (n=226) vs 10.9% (n=131) placebo @ 2wk200 mg
NCT03720470 · Phase 3
57.4% (n=226) vs 15.6% (n=131) placebo @ 4wk200 mg
NCT03720470 · Phase 3
67.9% (n=226) vs 18.6% (n=131) placebo @ 8wk200 mg
NCT03720470 · Phase 3
71% (n=226) vs 30.6% (n=131) placebo @ 16wk200 mg
NCT03720470 · Phase 3
72% (n=93) vs 41.5% (n=94) placebo @ 12wk200mg QD
NCT03796676 · Phase 3
25.5% (n=94) vs 4.4% (n=96) placebo @ 2wk200mg QD
NCT03796676 · Phase 3
63.8% (n=94) vs 14.6% (n=96) placebo @ 4wk200mg QD
NCT03796676 · Phase 3
68.5% (n=94) vs 33.3% (n=96) placebo @ 8wk200mg QD
NCT03796676 · Phase 3
99.6% (n=266) vs 99.2% (n=267) placebo @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
92.5% (n=266) vs 27% (n=267) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
80.5% (n=266) vs 18% (n=267) placebo @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
71.8% (n=266) vs 15.1% (n=267) placebo @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
65.8% (n=266) vs 14% (n=267) placebo @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
38.5% (n=14) vs 0% (n=16) placebo @ 2wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
50% (n=14) vs 0% (n=16) placebo @ 4wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
78.6% (n=14) vs 0% (n=16) placebo @ 8wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
78.6% (n=14) vs 0% (n=16) placebo @ 12wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
16.7% (n=55) vs 3.7% (n=56) placebo @ 1wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
36.5% (n=55) vs 5.5% (n=56) placebo @ 2wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
57.4% (n=55) vs 10.9% (n=56) placebo @ 4wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
68.5% (n=55) vs 16.4% (n=56) placebo @ 6wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
73.6% (n=55) vs 20% (n=56) placebo @ 8wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
64.6% (n=55) vs 15.4% (n=56) placebo @ 12wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
55.6% (n=55) vs 26.7% (n=56) placebo @ 13wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
45.5% (n=55) vs 31.3% (n=56) placebo @ 14wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
36.8% (n=55) vs 32.1% (n=56) placebo @ 16wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
6% (n=51) vs 3.7% (n=56) placebo @ 1wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
6% (n=51) vs 5.5% (n=56) placebo @ 2wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
20% (n=51) vs 10.9% (n=56) placebo @ 4wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
18% (n=51) vs 16.4% (n=56) placebo @ 6wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
22% (n=51) vs 20% (n=56) placebo @ 8wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
13.3% (n=51) vs 15.4% (n=56) placebo @ 12wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
12.9% (n=51) vs 26.7% (n=56) placebo @ 13wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
6.9% (n=51) vs 31.3% (n=56) placebo @ 14wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
3.7% (n=51) vs 32.1% (n=56) placebo @ 16wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
2.1% (n=49) vs 3.7% (n=56) placebo @ 1wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
12.2% (n=49) vs 5.5% (n=56) placebo @ 2wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
18.4% (n=49) vs 10.9% (n=56) placebo @ 4wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
18.4% (n=49) vs 16.4% (n=56) placebo @ 6wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
22.4% (n=49) vs 20% (n=56) placebo @ 8wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
17.4% (n=49) vs 15.4% (n=56) placebo @ 12wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
27.6% (n=49) vs 26.7% (n=56) placebo @ 13wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
25% (n=49) vs 31.3% (n=56) placebo @ 14wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
38.5% (n=49) vs 32.1% (n=56) placebo @ 16wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
Pruritus NRS 4-point Improvement 20.4% (n=147) vs 2.7% (n=74) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 31 more results
32.2% (n=147) vs 17.2% (n=74) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
34.3% (n=147) vs 14.4% (n=74) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
37.7% (n=147) vs 15.3% (n=74) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
20.5% (n=127) vs 3.7% (n=54) placebo @ 2wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
34% (n=127) vs 20.7% (n=54) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
41.1% (n=127) vs 12.3% (n=54) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
23.1% (n=156) vs 3.9% (n=76) placebo @ 2wk100 mg
NCT03575871 · Phase 3
31.4% (n=156) vs 3.9% (n=76) placebo @ 4wk100 mg
NCT03575871 · Phase 3
39.1% (n=156) vs 11.8% (n=76) placebo @ 8wk100 mg
NCT03575871 · Phase 3
39.7% (n=156) vs 10.5% (n=76) placebo @ 12wk100 mg
NCT03575871 · Phase 3
84% (n=254) vs 82.2% (n=258) placebo @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
54.6% (n=254) vs 15.9% (n=258) placebo @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
45% (n=254) vs 11.6% (n=258) placebo @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
39.4% (n=254) vs 10.1% (n=258) placebo @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
27.6% (n=254) vs 8.3% (n=258) placebo @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
45.6% (n=147) vs 2.7% (n=74) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
58.8% (n=147) vs 17.2% (n=74) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
59.9% (n=147) vs 14.4% (n=74) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
57.2% (n=147) vs 15.3% (n=74) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
47.6% (n=126) vs 3.7% (n=54) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
63.3% (n=126) vs 20.7% (n=54) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
60.6% (n=126) vs 12.3% (n=54) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
35.3% (n=153) vs 3.9% (n=76) placebo @ 2wk200 mg
NCT03575871 · Phase 3
50.3% (n=153) vs 3.9% (n=76) placebo @ 4wk200 mg
NCT03575871 · Phase 3
51.6% (n=153) vs 11.8% (n=76) placebo @ 8wk200 mg
NCT03575871 · Phase 3
49% (n=153) vs 10.5% (n=76) placebo @ 12wk200 mg
NCT03575871 · Phase 3
81.9% (n=250) vs 82.2% (n=258) placebo @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
75.6% (n=250) vs 15.9% (n=258) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
66.9% (n=250) vs 11.6% (n=258) placebo @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
55.7% (n=250) vs 10.1% (n=258) placebo @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
49% (n=250) vs 8.3% (n=258) placebo @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
PSAAD -1.5 vs -0.5 placebo score @ 2wk100 mg
absolute change · score
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 55 more results
-1.8 vs -0.7 placebo score @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.2 vs -1.2 placebo score @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.2 vs -1.1 placebo score @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.4 vs -1.1 placebo score @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.4 vs -0.8 placebo score @ 12wk100 mg
NCT03575871 · Phase 3
-1.1 vs -0.5 placebo score @ 1wk100 mg
NCT03720470 · Phase 3
-1.8 vs -0.9 placebo score @ 2wk100 mg
NCT03720470 · Phase 3
-2.2 vs -1.1 placebo score @ 3wk100 mg
NCT03720470 · Phase 3
-2.4 vs -1.4 placebo score @ 4wk100 mg
NCT03720470 · Phase 3
-2.6 vs -1.5 placebo score @ 5wk100 mg
NCT03720470 · Phase 3
-2.6 vs -1.5 placebo score @ 6wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.6 placebo score @ 7wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.5 placebo score @ 8wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.7 placebo score @ 9wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.7 placebo score @ 10wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.6 placebo score @ 11wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.6 placebo score @ 12wk100 mg
NCT03720470 · Phase 3
-2.8 vs -1.7 placebo score @ 13wk100 mg
NCT03720470 · Phase 3
-2.8 vs -1.6 placebo score @ 14wk100 mg
NCT03720470 · Phase 3
-2.9 vs -1.7 placebo score @ 15wk100 mg
NCT03720470 · Phase 3
-2.8 vs -1.7 placebo score @ 16wk100 mg
NCT03720470 · Phase 3
-2.5 vs -2 placebo score @ 12wk100mg QD
NCT03796676 · Phase 3
-4.2 vs -4.1 placebo score @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.8 vs 2.1 placebo score @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1 vs 2.3 placebo score @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1 vs 2 placebo score @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.2 vs 1.9 placebo score @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-2.1 vs -0.5 placebo score @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3 vs -0.7 placebo score @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.1 vs -1.2 placebo score @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.2 vs -1.1 placebo score @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.4 vs -1.1 placebo score @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3 vs -0.8 placebo score @ 12wk200 mg
NCT03575871 · Phase 3
-1.3 vs -0.5 placebo score @ 1wk200 mg
NCT03720470 · Phase 3
-2.3 vs -0.9 placebo score @ 2wk200 mg
NCT03720470 · Phase 3
-2.8 vs -1.1 placebo score @ 3wk200 mg
NCT03720470 · Phase 3
-3 vs -1.4 placebo score @ 4wk200 mg
NCT03720470 · Phase 3
-3.2 vs -1.5 placebo score @ 5wk200 mg
NCT03720470 · Phase 3
-3.3 vs -1.5 placebo score @ 6wk200 mg
NCT03720470 · Phase 3
-3.4 vs -1.6 placebo score @ 7wk200 mg
NCT03720470 · Phase 3
-3.4 vs -1.5 placebo score @ 8wk200 mg
NCT03720470 · Phase 3
-3.5 vs -1.7 placebo score @ 9wk200 mg
NCT03720470 · Phase 3
-3.5 vs -1.7 placebo score @ 10wk200 mg
NCT03720470 · Phase 3
-3.5 vs -1.6 placebo score @ 11wk200 mg
NCT03720470 · Phase 3
-3.6 vs -1.6 placebo score @ 12wk200 mg
NCT03720470 · Phase 3
-3.7 vs -1.7 placebo score @ 13wk200 mg
NCT03720470 · Phase 3
-3.6 vs -1.6 placebo score @ 14wk200 mg
NCT03720470 · Phase 3
-3.6 vs -1.7 placebo score @ 15wk200 mg
NCT03720470 · Phase 3
-3.6 vs -1.7 placebo score @ 16wk200 mg
NCT03720470 · Phase 3
-2.7 vs -2 placebo score @ 12wk200mg QD
NCT03796676 · Phase 3
-4.2 vs -4.1 placebo score @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.1 vs 2.1 placebo score @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.1 vs 2.3 placebo score @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.3 vs 2 placebo score @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.2 vs 1.9 placebo score @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
Time to Response 2.76 vs 3.02 placebo months100 mg
time to event · months
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 · converted to months from 84 days as posted
show 2 more results
0.46 vs 3.02 placebo months*200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 · converted to months from 14 days as posted
0.36 vs 0.82 Dupilumab months*200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 · converted to months from 11 days as posted
IGA 0 0% (n=156) vs 0% (n=77) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
0% (n=156) vs 0% (n=77) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.6% (n=156) vs 0% (n=77) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
7.1% (n=156) vs 0% (n=77) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0% (n=158) vs 0% (n=78) placebo @ 2wk100 mg
NCT03575871 · Phase 3
1.9% (n=158) vs 0% (n=78) placebo @ 4wk100 mg
NCT03575871 · Phase 3
1.3% (n=158) vs 0% (n=78) placebo @ 8wk100 mg
NCT03575871 · Phase 3
5.2% (n=158) vs 0% (n=78) placebo @ 12wk100 mg
NCT03575871 · Phase 3
0% (n=154) vs 0% (n=77) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.6% (n=154) vs 0% (n=77) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.7% (n=154) vs 0% (n=77) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
13.1% (n=154) vs 0% (n=77) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2% (n=155) vs 0% (n=78) placebo @ 2wk200 mg
NCT03575871 · Phase 3
4.6% (n=155) vs 0% (n=78) placebo @ 4wk200 mg
NCT03575871 · Phase 3
4.5% (n=155) vs 0% (n=78) placebo @ 8wk200 mg
NCT03575871 · Phase 3
6.5% (n=155) vs 0% (n=78) placebo @ 12wk200 mg
NCT03575871 · Phase 3
EASI-50 34.2% (n=156) vs 10.4% (n=77) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 87 more results
54.6% (n=156) vs 21.1% (n=77) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
57.8% (n=156) vs 24% (n=77) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
57.7% (n=156) vs 22.4% (n=77) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
35.7% (n=158) vs 10.5% (n=78) placebo @ 2wk100 mg
NCT03575871 · Phase 3
58.7% (n=158) vs 28.6% (n=78) placebo @ 4wk100 mg
NCT03575871 · Phase 3
66.2% (n=158) vs 34.6% (n=78) placebo @ 8wk100 mg
NCT03575871 · Phase 3
68.4% (n=158) vs 19.5% (n=78) placebo @ 12wk100 mg
NCT03575871 · Phase 3
53.1% (n=238) vs 21.9% (n=131) placebo @ 2wk100 mg
NCT03720470 · Phase 3
73.4% (n=238) vs 39.8% (n=131) placebo @ 4wk100 mg
NCT03720470 · Phase 3
78.9% (n=238) vs 48.8% (n=131) placebo @ 8wk100 mg
NCT03720470 · Phase 3
75.3% (n=238) vs 52.7% (n=131) placebo @ 12wk100 mg
NCT03720470 · Phase 3
81.2% (n=238) vs 57.3% (n=131) placebo @ 16wk100 mg
NCT03720470 · Phase 3
55.4% (n=92) vs 24.2% (n=96) placebo @ 2wk100mg QD
NCT03796676 · Phase 3
75% (n=92) vs 51% (n=96) placebo @ 4wk100mg QD
NCT03796676 · Phase 3
85.7% (n=92) vs 65.6% (n=96) placebo @ 8wk100mg QD
NCT03796676 · Phase 3
87.6% (n=92) vs 69.1% (n=96) placebo @ 12wk100mg QD
NCT03796676 · Phase 3
100% (n=264) vs 100% (n=267) placebo @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
83.3% (n=264) vs 40.8% (n=267) placebo @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
68.1% (n=264) vs 22.8% (n=267) placebo @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
57.3% (n=264) vs 16.6% (n=267) placebo @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
50.8% (n=264) vs 15.9% (n=267) placebo @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
37.5% (n=16) vs 12.5% (n=16) placebo @ 2wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
66.7% (n=16) vs 6.7% (n=16) placebo @ 4wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
53.3% (n=16) vs 6.7% (n=16) placebo @ 8wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
68.8% (n=16) vs 18.8% (n=16) placebo @ 12wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
12.7% (n=56) vs 9.3% (n=56) placebo @ 1wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
36.4% (n=56) vs 27.3% (n=56) placebo @ 2wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
58.2% (n=56) vs 27.3% (n=56) placebo @ 4wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
60% (n=56) vs 36.4% (n=56) placebo @ 6wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
60% (n=56) vs 30.9% (n=56) placebo @ 8wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
55.6% (n=56) vs 26.9% (n=56) placebo @ 12wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
55.3% (n=56) vs 43.3% (n=56) placebo @ 13wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
50% (n=56) vs 37.5% (n=56) placebo @ 14wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
41.7% (n=56) vs 42.9% (n=56) placebo @ 16wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
55.2% (n=154) vs 10.4% (n=77) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
73.7% (n=154) vs 21.1% (n=77) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
76.6% (n=154) vs 24% (n=77) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
75.8% (n=154) vs 22.4% (n=77) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
55.3% (n=155) vs 10.5% (n=78) placebo @ 2wk200 mg
NCT03575871 · Phase 3
78.4% (n=155) vs 28.6% (n=78) placebo @ 4wk200 mg
NCT03575871 · Phase 3
82.5% (n=155) vs 34.6% (n=78) placebo @ 8wk200 mg
NCT03575871 · Phase 3
79.9% (n=155) vs 19.5% (n=78) placebo @ 12wk200 mg
NCT03575871 · Phase 3
60.5% (n=226) vs 21.9% (n=131) placebo @ 2wk200 mg
NCT03720470 · Phase 3
78.5% (n=226) vs 39.8% (n=131) placebo @ 4wk200 mg
NCT03720470 · Phase 3
88.4% (n=226) vs 48.8% (n=131) placebo @ 8wk200 mg
NCT03720470 · Phase 3
86.3% (n=226) vs 52.7% (n=131) placebo @ 12wk200 mg
NCT03720470 · Phase 3
87.3% (n=226) vs 57.3% (n=131) placebo @ 16wk200 mg
NCT03720470 · Phase 3
64.9% (n=94) vs 24.2% (n=96) placebo @ 2wk200mg QD
NCT03796676 · Phase 3
81.9% (n=94) vs 51% (n=96) placebo @ 4wk200mg QD
NCT03796676 · Phase 3
82.6% (n=94) vs 65.6% (n=96) placebo @ 8wk200mg QD
NCT03796676 · Phase 3
87.1% (n=94) vs 69.1% (n=96) placebo @ 12wk200mg QD
NCT03796676 · Phase 3
100% (n=266) vs 100% (n=267) placebo @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
96.2% (n=266) vs 40.8% (n=267) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
85.9% (n=266) vs 22.8% (n=267) placebo @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
74.9% (n=266) vs 16.6% (n=267) placebo @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
71.2% (n=266) vs 15.9% (n=267) placebo @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
61.5% (n=14) vs 12.5% (n=16) placebo @ 2wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
100% (n=14) vs 6.7% (n=16) placebo @ 4wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
100% (n=14) vs 6.7% (n=16) placebo @ 8wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
92.9% (n=14) vs 18.8% (n=16) placebo @ 12wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
40.7% (n=55) vs 9.3% (n=56) placebo @ 1wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
65.4% (n=55) vs 27.3% (n=56) placebo @ 2wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
85.2% (n=55) vs 27.3% (n=56) placebo @ 4wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
90.7% (n=55) vs 36.4% (n=56) placebo @ 6wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
90.6% (n=55) vs 30.9% (n=56) placebo @ 8wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
79.2% (n=55) vs 26.9% (n=56) placebo @ 12wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
75.6% (n=55) vs 43.3% (n=56) placebo @ 13wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
65.9% (n=55) vs 37.5% (n=56) placebo @ 14wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
68.4% (n=55) vs 42.9% (n=56) placebo @ 16wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
14% (n=51) vs 9.3% (n=56) placebo @ 1wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
24% (n=51) vs 27.3% (n=56) placebo @ 2wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
36% (n=51) vs 27.3% (n=56) placebo @ 4wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
40% (n=51) vs 36.4% (n=56) placebo @ 6wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
40% (n=51) vs 30.9% (n=56) placebo @ 8wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
33.3% (n=51) vs 26.9% (n=56) placebo @ 12wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
45.2% (n=51) vs 43.3% (n=56) placebo @ 13wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
37.9% (n=51) vs 37.5% (n=56) placebo @ 14wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
33.3% (n=51) vs 42.9% (n=56) placebo @ 16wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
8.3% (n=49) vs 9.3% (n=56) placebo @ 1wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
16.3% (n=49) vs 27.3% (n=56) placebo @ 2wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
30.6% (n=49) vs 27.3% (n=56) placebo @ 4wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
30.6% (n=49) vs 36.4% (n=56) placebo @ 6wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
36.7% (n=49) vs 30.9% (n=56) placebo @ 8wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
26.1% (n=49) vs 26.9% (n=56) placebo @ 12wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
41.4% (n=49) vs 43.3% (n=56) placebo @ 13wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
42.9% (n=49) vs 37.5% (n=56) placebo @ 14wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
42.3% (n=49) vs 42.9% (n=56) placebo @ 16wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
EASI-90 1.9% (n=156) vs 1.3% (n=77) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 94 more results
7.9% (n=156) vs 3.9% (n=77) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
14.3% (n=156) vs 5.3% (n=77) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
18.6% (n=156) vs 5.3% (n=77) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.5% (n=158) vs 0% (n=78) placebo @ 2wk100 mg
NCT03575871 · Phase 3
9.7% (n=158) vs 0% (n=78) placebo @ 4wk100 mg
NCT03575871 · Phase 3
17.2% (n=158) vs 2.6% (n=78) placebo @ 8wk100 mg
NCT03575871 · Phase 3
23.9% (n=158) vs 3.9% (n=78) placebo @ 12wk100 mg
NCT03575871 · Phase 3
8.3% (n=238) vs 2.3% (n=131) placebo @ 2wk100 mg
NCT03720470 · Phase 3
20.2% (n=238) vs 6.3% (n=131) placebo @ 4wk100 mg
NCT03720470 · Phase 3
30.6% (n=238) vs 7.8% (n=131) placebo @ 8wk100 mg
NCT03720470 · Phase 3
36.6% (n=238) vs 10.1% (n=131) placebo @ 12wk100 mg
NCT03720470 · Phase 3
38% (n=238) vs 11.3% (n=131) placebo @ 16wk100 mg
NCT03720470 · Phase 3
8.7% (n=92) vs 0% (n=96) placebo @ 2wk100mg QD
NCT03796676 · Phase 3
17.4% (n=92) vs 2.1% (n=96) placebo @ 4wk100mg QD
NCT03796676 · Phase 3
29.7% (n=92) vs 14% (n=96) placebo @ 8wk100mg QD
NCT03796676 · Phase 3
41.6% (n=92) vs 18.1% (n=96) placebo @ 12wk100mg QD
NCT03796676 · Phase 3
87.1% (n=264) vs 84.6% (n=267) placebo @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
51.3% (n=264) vs 13.9% (n=267) placebo @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
46.9% (n=264) vs 10.5% (n=267) placebo @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
41.5% (n=264) vs 12.1% (n=267) placebo @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
37.6% (n=264) vs 10.6% (n=267) placebo @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0% (n=16) vs 0% (n=16) placebo @ 2wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
20% (n=16) vs 0% (n=16) placebo @ 4wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
20% (n=16) vs 0% (n=16) placebo @ 8wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
37.5% (n=16) vs 0% (n=16) placebo @ 12wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
0% (n=56) vs 0% (n=56) placebo @ 1wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
5.5% (n=56) vs 0% (n=56) placebo @ 2wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
10.9% (n=56) vs 1.8% (n=56) placebo @ 4wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
16.4% (n=56) vs 7.3% (n=56) placebo @ 6wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
23.6% (n=56) vs 5.5% (n=56) placebo @ 8wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
25.9% (n=56) vs 9.6% (n=56) placebo @ 12wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
23.7% (n=56) vs 10% (n=56) placebo @ 13wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
17.5% (n=56) vs 15.6% (n=56) placebo @ 14wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
8.3% (n=56) vs 14.3% (n=56) placebo @ 16wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
5.2% (n=154) vs 1.3% (n=77) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
24.3% (n=154) vs 3.9% (n=77) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
33.1% (n=154) vs 5.3% (n=77) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
38.6% (n=154) vs 5.3% (n=77) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
28.5% (n=354) vs 14.6% (n=364) Dupilumab @ 4wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
54.3% (n=357) vs 41.9% (n=360) Dupilumab @ 16wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.6% (n=362) vs 7.2% (n=365) Dupilumab @ 2wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
45.4% (n=362) vs 25.4% (n=365) Dupilumab @ 8wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
47.6% (n=362) vs 33.6% (n=365) Dupilumab @ 12wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
58.4% (n=362) vs 45.7% (n=365) Dupilumab @ 20wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
54.6% (n=362) vs 47.6% (n=365) Dupilumab @ 26wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
9.2% (n=155) vs 0% (n=78) placebo @ 2wk200 mg
NCT03575871 · Phase 3
22.9% (n=155) vs 0% (n=78) placebo @ 4wk200 mg
NCT03575871 · Phase 3
34.4% (n=155) vs 2.6% (n=78) placebo @ 8wk200 mg
NCT03575871 · Phase 3
37.7% (n=155) vs 3.9% (n=78) placebo @ 12wk200 mg
NCT03575871 · Phase 3
11.2% (n=226) vs 2.3% (n=131) placebo @ 2wk200 mg
NCT03720470 · Phase 3
32.3% (n=226) vs 6.3% (n=131) placebo @ 4wk200 mg
NCT03720470 · Phase 3
47.3% (n=226) vs 7.8% (n=131) placebo @ 8wk200 mg
NCT03720470 · Phase 3
46.1% (n=226) vs 10.1% (n=131) placebo @ 12wk200 mg
NCT03720470 · Phase 3
48.9% (n=226) vs 11.3% (n=131) placebo @ 16wk200 mg
NCT03720470 · Phase 3
10.6% (n=94) vs 0% (n=96) placebo @ 2wk200mg QD
NCT03796676 · Phase 3
30.9% (n=94) vs 2.1% (n=96) placebo @ 4wk200mg QD
NCT03796676 · Phase 3
40.2% (n=94) vs 14% (n=96) placebo @ 8wk200mg QD
NCT03796676 · Phase 3
49.5% (n=94) vs 18.1% (n=96) placebo @ 12wk200mg QD
NCT03796676 · Phase 3
86.4% (n=266) vs 84.6% (n=267) placebo @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
77.1% (n=266) vs 13.9% (n=267) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
64.5% (n=266) vs 10.5% (n=267) placebo @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
58.7% (n=266) vs 12.1% (n=267) placebo @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
54.5% (n=266) vs 10.6% (n=267) placebo @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0% (n=14) vs 0% (n=16) placebo @ 2wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
28.6% (n=14) vs 0% (n=16) placebo @ 4wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
57.1% (n=14) vs 0% (n=16) placebo @ 8wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
50% (n=14) vs 0% (n=16) placebo @ 12wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
7.4% (n=55) vs 0% (n=56) placebo @ 1wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
19.2% (n=55) vs 0% (n=56) placebo @ 2wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
38.9% (n=55) vs 1.8% (n=56) placebo @ 4wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
44.4% (n=55) vs 7.3% (n=56) placebo @ 6wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
43.4% (n=55) vs 5.5% (n=56) placebo @ 8wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
52.1% (n=55) vs 9.6% (n=56) placebo @ 12wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
31.1% (n=55) vs 10% (n=56) placebo @ 13wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
18.2% (n=55) vs 15.6% (n=56) placebo @ 14wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
10.5% (n=55) vs 14.3% (n=56) placebo @ 16wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
4% (n=51) vs 0% (n=56) placebo @ 1wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
4% (n=51) vs 0% (n=56) placebo @ 2wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
8% (n=51) vs 1.8% (n=56) placebo @ 4wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
14% (n=51) vs 7.3% (n=56) placebo @ 6wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
8% (n=51) vs 5.5% (n=56) placebo @ 8wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
0% (n=51) vs 9.6% (n=56) placebo @ 12wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
3.2% (n=51) vs 10% (n=56) placebo @ 13wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
0% (n=51) vs 15.6% (n=56) placebo @ 14wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
3.7% (n=51) vs 14.3% (n=56) placebo @ 16wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
2.1% (n=49) vs 0% (n=56) placebo @ 1wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
6.1% (n=49) vs 0% (n=56) placebo @ 2wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
8.2% (n=49) vs 1.8% (n=56) placebo @ 4wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
14.3% (n=49) vs 7.3% (n=56) placebo @ 6wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
12.2% (n=49) vs 5.5% (n=56) placebo @ 8wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
10.9% (n=49) vs 9.6% (n=56) placebo @ 12wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
13.8% (n=49) vs 10% (n=56) placebo @ 13wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
14.3% (n=49) vs 15.6% (n=56) placebo @ 14wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
23.1% (n=49) vs 14.3% (n=56) placebo @ 16wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
EASI 100 0% (n=156) vs 0% (n=77) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 43 more results
0% (n=156) vs 0% (n=77) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.5% (n=156) vs 0% (n=77) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.4% (n=156) vs 0% (n=77) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0% (n=158) vs 0% (n=78) placebo @ 2wk100 mg
NCT03575871 · Phase 3
1.3% (n=158) vs 0% (n=78) placebo @ 4wk100 mg
NCT03575871 · Phase 3
1.3% (n=158) vs 0% (n=78) placebo @ 8wk100 mg
NCT03575871 · Phase 3
5.2% (n=158) vs 0% (n=78) placebo @ 12wk100 mg
NCT03575871 · Phase 3
1.3% (n=238) vs 0% (n=131) placebo @ 2wk100 mg
NCT03720470 · Phase 3
2.6% (n=238) vs 0% (n=131) placebo @ 4wk100 mg
NCT03720470 · Phase 3
6% (n=238) vs 0% (n=131) placebo @ 8wk100 mg
NCT03720470 · Phase 3
8.1% (n=238) vs 1.6% (n=131) placebo @ 12wk100 mg
NCT03720470 · Phase 3
12.7% (n=238) vs 4% (n=131) placebo @ 16wk100 mg
NCT03720470 · Phase 3
1.1% (n=92) vs 0% (n=96) placebo @ 2wk100mg QD
NCT03796676 · Phase 3
2.2% (n=92) vs 0% (n=96) placebo @ 4wk100mg QD
NCT03796676 · Phase 3
3.3% (n=92) vs 0% (n=96) placebo @ 8wk100mg QD
NCT03796676 · Phase 3
2.2% (n=92) vs 2.1% (n=96) placebo @ 12wk100mg QD
NCT03796676 · Phase 3
30.3% (n=264) vs 30.5% (n=267) placebo @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
15.2% (n=264) vs 3.7% (n=267) placebo @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
16.5% (n=264) vs 4.1% (n=267) placebo @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
15.8% (n=264) vs 4.5% (n=267) placebo @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
18.6% (n=264) vs 4.5% (n=267) placebo @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0% (n=154) vs 0% (n=77) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.6% (n=154) vs 0% (n=77) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.7% (n=154) vs 0% (n=77) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
13.1% (n=154) vs 0% (n=77) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.3% (n=155) vs 0% (n=78) placebo @ 2wk200 mg
NCT03575871 · Phase 3
3.9% (n=155) vs 0% (n=78) placebo @ 4wk200 mg
NCT03575871 · Phase 3
3.9% (n=155) vs 0% (n=78) placebo @ 8wk200 mg
NCT03575871 · Phase 3
7.1% (n=155) vs 0% (n=78) placebo @ 12wk200 mg
NCT03575871 · Phase 3
4.5% (n=226) vs 0% (n=131) placebo @ 2wk200 mg
NCT03720470 · Phase 3
7.2% (n=226) vs 0% (n=131) placebo @ 4wk200 mg
NCT03720470 · Phase 3
11.6% (n=226) vs 0% (n=131) placebo @ 8wk200 mg
NCT03720470 · Phase 3
12.3% (n=226) vs 1.6% (n=131) placebo @ 12wk200 mg
NCT03720470 · Phase 3
13.6% (n=226) vs 4% (n=131) placebo @ 16wk200 mg
NCT03720470 · Phase 3
0% (n=94) vs 0% (n=96) placebo @ 2wk200mg QD
NCT03796676 · Phase 3
5.3% (n=94) vs 0% (n=96) placebo @ 4wk200mg QD
NCT03796676 · Phase 3
9.8% (n=94) vs 0% (n=96) placebo @ 8wk200mg QD
NCT03796676 · Phase 3
8.6% (n=94) vs 2.1% (n=96) placebo @ 12wk200mg QD
NCT03796676 · Phase 3
28.3% (n=266) vs 30.5% (n=267) placebo @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
28.9% (n=266) vs 3.7% (n=267) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
30.2% (n=266) vs 4.1% (n=267) placebo @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
30.1% (n=266) vs 4.5% (n=267) placebo @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
28.8% (n=266) vs 4.5% (n=267) placebo @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
EASI -9.8 vs -4.1 placebo score @ 2wk100 mg
absolute change · score
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 7 more results
-14.7 vs -6.8 placebo score @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-16.3 vs -7.8 placebo score @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-16.6 vs -8.2 placebo score @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-14.7 vs -4.1 placebo score @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-19.6 vs -6.8 placebo score @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-21.3 vs -7.8 placebo score @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-22.3 vs -8.2 placebo score @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
BSA -11.8% (n=156) vs -4% (n=77) placebo @ 2wk100 mg
absolute change · percentage points
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 94 more results
-20.2% (n=156) vs -8.5% (n=77) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-23.2% (n=156) vs -8.9% (n=77) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-25.1% (n=156) vs -11.4% (n=77) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-27.8% (n=158) vs -1.3% (n=78) placebo @ 2wk100 mg
NCT03575871 · Phase 3
-45% (n=158) vs -15.3% (n=78) placebo @ 4wk100 mg
NCT03575871 · Phase 3
-53.4% (n=158) vs -20.5% (n=78) placebo @ 8wk100 mg
NCT03575871 · Phase 3
-56.4% (n=158) vs -16.8% (n=78) placebo @ 12wk100 mg
NCT03575871 · Phase 3
-19.5% (n=238) vs -7.6% (n=131) placebo @ 2wk100 mg
NCT03720470 · Phase 3
-26.8% (n=238) vs -14.3% (n=131) placebo @ 4wk100 mg
NCT03720470 · Phase 3
-30.3% (n=238) vs -16.2% (n=131) placebo @ 8wk100 mg
NCT03720470 · Phase 3
-31.6% (n=238) vs -17.1% (n=131) placebo @ 12wk100 mg
NCT03720470 · Phase 3
-32.9% (n=238) vs -19.6% (n=131) placebo @ 16wk100 mg
NCT03720470 · Phase 3
-40.4% (n=95) vs -20.6% (n=96) placebo @ 2wk100mg QD
NCT03796676 · Phase 3
-55.4% (n=95) vs -29% (n=96) placebo @ 4wk100mg QD
NCT03796676 · Phase 3
-65.7% (n=95) vs -46% (n=96) placebo @ 8wk100mg QD
NCT03796676 · Phase 3
-71.4% (n=95) vs -53.4% (n=96) placebo @ 12wk100mg QD
NCT03796676 · Phase 3
-96.7% (n=264) vs -95.6% (n=266) placebo @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-90.9% (n=264) vs -68.5% (n=266) placebo @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-93.8% (n=264) vs -85.2% (n=266) placebo @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-95.8% (n=264) vs -91.2% (n=266) placebo @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-96.9% (n=264) vs -91.5% (n=266) placebo @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-9.6% (n=16) vs 4% (n=16) placebo @ 2wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
-18.7% (n=16) vs 2.1% (n=16) placebo @ 4wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
-18.7% (n=16) vs 0.2% (n=16) placebo @ 8wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
-22% (n=16) vs -0.2% (n=16) placebo @ 12wk100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
-4.63% (n=56) vs -0.06% (n=56) placebo @ 1wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-10.8% (n=56) vs -5.43% (n=56) placebo @ 2wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-17.77% (n=56) vs -6.34% (n=56) placebo @ 4wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-18.8% (n=56) vs -10.79% (n=56) placebo @ 6wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-19.41% (n=56) vs -9.71% (n=56) placebo @ 8wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-22.21% (n=56) vs -13.82% (n=56) placebo @ 12wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-17.88% (n=56) vs -7.9% (n=56) placebo @ 13wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-12.75% (n=56) vs -8.97% (n=56) placebo @ 14wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-5.55% (n=56) vs -8.09% (n=56) placebo @ 16wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-18.8% (n=154) vs -4% (n=77) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-27% (n=154) vs -8.5% (n=77) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-31.5% (n=154) vs -8.9% (n=77) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-33.4% (n=154) vs -11.4% (n=77) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-42.7% (n=362) vs -33.4% (n=365) Dupilumab @ 2wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-62% (n=362) vs -49.5% (n=365) Dupilumab @ 4wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-74% (n=362) vs -62.8% (n=365) Dupilumab @ 8wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-78.8% (n=362) vs -69.4% (n=365) Dupilumab @ 12wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-80.6% (n=362) vs -73.7% (n=365) Dupilumab @ 16wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-82.2% (n=362) vs -76.9% (n=365) Dupilumab @ 20wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-82.3% (n=362) vs -79% (n=365) Dupilumab @ 26wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-35.4% (n=155) vs -1.3% (n=78) placebo @ 2wk200 mg
NCT03575871 · Phase 3
-55.7% (n=155) vs -15.3% (n=78) placebo @ 4wk200 mg
NCT03575871 · Phase 3
-61.1% (n=155) vs -20.5% (n=78) placebo @ 8wk200 mg
NCT03575871 · Phase 3
-65% (n=155) vs -16.8% (n=78) placebo @ 12wk200 mg
NCT03575871 · Phase 3
-21.4% (n=226) vs -7.6% (n=131) placebo @ 2wk200 mg
NCT03720470 · Phase 3
-30.7% (n=226) vs -14.3% (n=131) placebo @ 4wk200 mg
NCT03720470 · Phase 3
-36.4% (n=226) vs -16.2% (n=131) placebo @ 8wk200 mg
NCT03720470 · Phase 3
-37.4% (n=226) vs -17.1% (n=131) placebo @ 12wk200 mg
NCT03720470 · Phase 3
-39% (n=226) vs -19.6% (n=131) placebo @ 16wk200 mg
NCT03720470 · Phase 3
-42.2% (n=94) vs -20.6% (n=96) placebo @ 2wk200mg QD
NCT03796676 · Phase 3
-66% (n=94) vs -29% (n=96) placebo @ 4wk200mg QD
NCT03796676 · Phase 3
-69.5% (n=94) vs -46% (n=96) placebo @ 8wk200mg QD
NCT03796676 · Phase 3
-72.6% (n=94) vs -53.4% (n=96) placebo @ 12wk200mg QD
NCT03796676 · Phase 3
-96.7% (n=265) vs -95.6% (n=266) placebo @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-96.3% (n=265) vs -68.5% (n=266) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-96.4% (n=265) vs -85.2% (n=266) placebo @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-96.8% (n=265) vs -91.2% (n=266) placebo @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-96.9% (n=265) vs -91.5% (n=266) placebo @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-17.3% (n=14) vs 4% (n=16) placebo @ 2wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
-23.8% (n=14) vs 2.1% (n=16) placebo @ 4wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
-28.3% (n=14) vs 0.2% (n=16) placebo @ 8wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
-28.3% (n=14) vs -0.2% (n=16) placebo @ 12wk200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
-10.86% (n=55) vs -0.06% (n=56) placebo @ 1wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-21.3% (n=55) vs -5.43% (n=56) placebo @ 2wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-28.55% (n=55) vs -6.34% (n=56) placebo @ 4wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-30.51% (n=55) vs -10.79% (n=56) placebo @ 6wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-29.98% (n=55) vs -9.71% (n=56) placebo @ 8wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-27.72% (n=55) vs -13.82% (n=56) placebo @ 12wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-22.61% (n=55) vs -7.9% (n=56) placebo @ 13wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-16.35% (n=55) vs -8.97% (n=56) placebo @ 14wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-17.88% (n=55) vs -8.09% (n=56) placebo @ 16wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-2.45% (n=51) vs -0.06% (n=56) placebo @ 1wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-6.51% (n=51) vs -5.43% (n=56) placebo @ 2wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-9.59% (n=51) vs -6.34% (n=56) placebo @ 4wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-10.71% (n=51) vs -10.79% (n=56) placebo @ 6wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-10.79% (n=51) vs -9.71% (n=56) placebo @ 8wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-9.37% (n=51) vs -13.82% (n=56) placebo @ 12wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-7.79% (n=51) vs -7.9% (n=56) placebo @ 13wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-6.33% (n=51) vs -8.97% (n=56) placebo @ 14wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-3.52% (n=51) vs -8.09% (n=56) placebo @ 16wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-3.76% (n=49) vs -0.06% (n=56) placebo @ 1wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-4.84% (n=49) vs -5.43% (n=56) placebo @ 2wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-8.93% (n=49) vs -6.34% (n=56) placebo @ 4wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-11.8% (n=49) vs -10.79% (n=56) placebo @ 6wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-12.98% (n=49) vs -9.71% (n=56) placebo @ 8wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-11.59% (n=49) vs -13.82% (n=56) placebo @ 12wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-11.07% (n=49) vs -7.9% (n=56) placebo @ 13wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-10.46% (n=49) vs -8.97% (n=56) placebo @ 14wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-14.64% (n=49) vs -8.09% (n=56) placebo @ 16wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
BSA Less Than 5 2.6% (n=156) vs 1.3% (n=77) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
8.6% (n=156) vs 3.9% (n=77) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
16.2% (n=156) vs 6.7% (n=77) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
21.2% (n=156) vs 5.3% (n=77) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.9% (n=158) vs 0% (n=78) placebo @ 2wk100 mg
NCT03575871 · Phase 3
6.5% (n=158) vs 0% (n=78) placebo @ 4wk100 mg
NCT03575871 · Phase 3
15.9% (n=158) vs 1.3% (n=78) placebo @ 8wk100 mg
NCT03575871 · Phase 3
22.6% (n=158) vs 3.9% (n=78) placebo @ 12wk100 mg
NCT03575871 · Phase 3
38.2% (n=89) vs 24.5% (n=94) placebo @ 12wk100mg QD
NCT03796676 · Phase 3
5.2% (n=154) vs 1.3% (n=77) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
27.6% (n=154) vs 3.9% (n=77) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
33.1% (n=154) vs 6.7% (n=77) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
38.6% (n=154) vs 5.3% (n=77) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
5.9% (n=155) vs 0% (n=78) placebo @ 2wk200 mg
NCT03575871 · Phase 3
17% (n=155) vs 0% (n=78) placebo @ 4wk200 mg
NCT03575871 · Phase 3
27.3% (n=155) vs 1.3% (n=78) placebo @ 8wk200 mg
NCT03575871 · Phase 3
34.4% (n=155) vs 3.9% (n=78) placebo @ 12wk200 mg
NCT03575871 · Phase 3
36.6% (n=93) vs 24.5% (n=94) placebo @ 12wk200mg QD
NCT03796676 · Phase 3

+ 129 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: abrocitinib's landscape · IN-115314's landscape